Neurocrine Biosciences, Inc. (NBIX)
After hours:
| Previous close | 146.10 |
| Open | 145.89 |
| Bid | 146.62 x 100 |
| Ask | 146.84 x 100 |
| Day's range | 144.35 - 148.02 |
| 52-week range | 99.98 - 150.39 |
| Volume | |
| Avg. volume | 757,811 |
| Market cap | 14.774B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 39.89 |
| EPS (TTM) | 3.68 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 160.72 |
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireNeurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA® SPRINKLE (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA.
ZacksImplied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
